Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1951 1
1955 1
1958 1
1959 1
1961 1
1962 3
1964 1
1965 1
1970 1
1971 4
1972 1
1974 1
1975 1
1978 3
1979 1
1980 3
1982 1
1983 2
1984 2
1985 4
1986 2
1987 3
1988 5
1989 2
1990 5
1991 6
1992 4
1993 7
1994 4
1995 3
1996 8
1997 8
1998 5
1999 4
2000 10
2001 9
2002 7
2003 5
2004 13
2005 21
2006 7
2007 21
2008 25
2009 38
2010 33
2011 45
2012 51
2013 65
2014 63
2015 101
2016 106
2017 116
2018 139
2019 152
2020 199
2021 225
2022 258
2023 292
2024 338
2025 100

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,280 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Mouabid
Page 1
Complement in Secondary Thrombotic Microangiopathy.
Palma LMP, Sridharan M, Sethi S. Palma LMP, et al. Kidney Int Rep. 2021 Jan;6(1):11-23. doi: 10.1016/j.ekir.2020.10.009. Epub 2020 Oct 21. Kidney Int Rep. 2021. PMID: 33102952 Free PMC article. Review.
Thrombotic microangiopathy (TMA) is a condition characterized by thrombocytopenia and microangiopathic hemolytic anemia (MAHA) with varying degrees of organ damage in the setting of normal international normalized ratio and activated partial thromboplastin time. ...
Thrombotic microangiopathy (TMA) is a condition characterized by thrombocytopenia and microangiopathic hemolytic anemia (MAHA) with v …
How I treat microangiopathic hemolytic anemia in patients with cancer.
Thomas MR, Scully M. Thomas MR, et al. Blood. 2021 Mar 11;137(10):1310-1317. doi: 10.1182/blood.2019003810. Blood. 2021. PMID: 33512445 Free PMC article. Review.
Microangiopathic hemolytic anemia (MAHA) with thrombocytopenia, suggests a thrombotic microangiopathy (TMA), linked with thrombus formation affecting small or larger vessels. ...We will discuss the differential diagnosis and treatment of MAHA in patients with cancer …
Microangiopathic hemolytic anemia (MAHA) with thrombocytopenia, suggests a thrombotic microangiopathy (TMA), linked with thrombus for …
A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies.
Scully M, Rayment R, Clark A, Westwood JP, Cranfield T, Gooding R, Bagot CN, Taylor A, Sankar V, Gale D, Dutt T, McIntyre J, Lester W; BSH Committee. Scully M, et al. Br J Haematol. 2023 Nov;203(4):546-563. doi: 10.1111/bjh.19026. Epub 2023 Aug 16. Br J Haematol. 2023. PMID: 37586700
The objective of this guideline is to provide healthcare professionals with clear, up-to-date and practical guidance on the management of thrombotic thrombocytopenic purpura (TTP) and related thrombotic microangiopathies (TMAs), including complement-mediated haemolytic uraemic sy …
The objective of this guideline is to provide healthcare professionals with clear, up-to-date and practical guidance on the management of th …
Carfilzomib‐Induced Thrombotic Microangiopathy—Two Case Reports.
Attucci I, Pilerci S, Messeri M, Pengue L, Tomasino G, Caroti L, Vannucchi AM, Antonioli E. Attucci I, et al. Cancer Rep (Hoboken). 2024 Oct;7(10):e2163. doi: 10.1002/cnr2.2163. Cancer Rep (Hoboken). 2024. PMID: 39390755 Free PMC article. Review. Spanish.
BACKGROUND: Thrombotic microangiopathy (TMA) is a pathological syndrome characterized by a combination of three key features: microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and organ damage, primarily affecting the kidneys. There are several drugs known to hav …
BACKGROUND: Thrombotic microangiopathy (TMA) is a pathological syndrome characterized by a combination of three key features: microangiopath …
Where have all the platelets gone? HIT, DIC, or something else?
Jesudas R, Takemoto CM. Jesudas R, et al. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):43-50. doi: 10.1182/hematology.2023000465. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066886 Free PMC article. Review.
Thrombocytopenia with microangiopathic hemolytic anemia (MAHA) is frequently due to disseminated intravascular coagulation. Thrombotic microangiopathy (TMA) is a subgroup of MAHA. ...
Thrombocytopenia with microangiopathic hemolytic anemia (MAHA) is frequently due to disseminated intravascular coagulation. Thromboti …
Syndromes of Thrombotic Microangiopathy.
Shatzel JJ, Taylor JA. Shatzel JJ, et al. Med Clin North Am. 2017 Mar;101(2):395-415. doi: 10.1016/j.mcna.2016.09.010. Epub 2016 Dec 27. Med Clin North Am. 2017. PMID: 28189178 Review.
Thrombotic microangiopathy in cancer.
Weitz IC. Weitz IC. Thromb Res. 2018 Apr;164 Suppl 1:S103-S105. doi: 10.1016/j.thromres.2018.01.014. Epub 2018 Jan 9. Thromb Res. 2018. PMID: 29703465 Review.
Thrombotic microangiopathy (TMA) is clinical syndrome based on the presence of thrombocytopenia (platelet count <150 K or a reduction of the platelet count by >30% from baseline) accompanied by fragmentation hemolysis (MAHA) and evidence of organ damage. It can be se …
Thrombotic microangiopathy (TMA) is clinical syndrome based on the presence of thrombocytopenia (platelet count <150 K or a reduction of …
[Breast cancer-related thrombotic microangiopathy: A review].
Alhenc-Gelas M, Bidard FC. Alhenc-Gelas M, et al. Bull Cancer. 2021 Jul-Aug;108(7-8):730-739. doi: 10.1016/j.bulcan.2021.03.017. Epub 2021 May 26. Bull Cancer. 2021. PMID: 34052032 Review. French.
We conducted a review of all original published cases of TM reported in breast cancer, and we specifically investigated BC-MAHA cases. A Medline search identified 158 MAHA cases including 118 BC-MAHA, and 40 drug-related MAHA. ...Incidence of coagulati …
We conducted a review of all original published cases of TM reported in breast cancer, and we specifically investigated BC-MAHA cases …
Recent Advances in the Management of Microangiopathic Hemolytic Anemias (MAHA): A Narrative Review.
Pande A, Kumar A, Krishnani H, Acharya S, Shukla S. Pande A, et al. Cureus. 2023 Oct 17;15(10):e47196. doi: 10.7759/cureus.47196. eCollection 2023 Oct. Cureus. 2023. PMID: 38021690 Free PMC article. Review.
Whenever the frequency of RBC breakdown is rapid enough to lower hemoglobin levels below the normal range, hemolytic anemia occurs. Microangiopathic hemolytic anemia (MAHA) is a term used to describe non-immune hemolysis induced by intravascular RBC fragmentation caused by …
Whenever the frequency of RBC breakdown is rapid enough to lower hemoglobin levels below the normal range, hemolytic anemia occurs. Microang …
[Hemolytic uremic syndrome].
Arai T, Matsuzaki K. Arai T, et al. Nihon Rinsho. 1996 Sep;54(9):2551-60. Nihon Rinsho. 1996. PMID: 8890593 Review. Japanese.
Hemolytic uremic syndrome (HUS) was first reported by Gasser in 1966 as a syndrome characterized by triadic symptomatology of microangiopathic hemolytic anemia (MAHA), thrombocytopenia and acute renal failure, affecting young children more than adults. ...
Hemolytic uremic syndrome (HUS) was first reported by Gasser in 1966 as a syndrome characterized by triadic symptomatology of microangiopath …
2,280 results